Neurobiological Technologies News

Jul 9, 2008 - Dutton Associates updates its coverage of Neurobiological Technologies maintaining a Strong Speculative Buy rating and a 12-month target price of $4. The 11-page report by Dutton senior analyst ...

Neurobiological Technologies, Inc. , today announced that Paul E. Freiman, president and chief executive officer , has announced his intent to retire on December 31, 2008.

President and CEO, Neurobiological Technologies Inc. San Francisco Business Times Background: Freiman is guiding a company trying to turn the venom of the Malayan pit viper into a stroke treatment called ...

“Viprinex, a novel Fibrinogen Reducing Agent, is an enzyme that reduces levels of fibrinogen, the primary protein involved in blood clotting”

Neurobiological Technologies, Inc. ) reported for the first time at the European Stroke Conference detailed analyses supporting the dosing regimen in NTI's two ongoing Phase 3 studies of Viprinex for ischemic ... via Med Ad News

Neurobiological Technologies, Inc. ) , today announced it will release its third quarter 2008 financial results, for the quarter ended March 31, 2008, on May 12, 2008 and host a conference call on May 13, 2008. via Med Ad News

Main Category: Stroke / Neuroprotection Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Neurobiological Technologies, Inc. via MediLexicon

“We have learned some valuable lessons from the failed trials”

The whole episode remains a blur to Kenneth Transeau of Katy, Texas, as he was flown by an air ambulance to a stroke center in Houston. via RedOrbit

Neurobiological Technologies Inc. has appointed Matthew Loar chief financial officer, replacing Craig Carlson. via Bizjournals

“Some products that were dogs could have a second or a third life.”

Silicon Valley / San Jose Business Journal - by Ron Leuty For Neurobiological Technologies Inc. via Bizjournals

“There is a lot of skepticism about any stroke drug due to the recent failures ... all this has frightened the large pharma companies”

As strokes remain to be the number 3 cause of death in the U.S., many researchers continue to struggle to find alternative methods of improving the odds of recovery. via RedOrbit

“We look forward to this second important research and development partnership for underserved CNS disorders that affect an increasing number of people worldwide.”

Neurobiological Technologies, Inc. and the Buck Institute for Age Research announced today they have entered into a collaboration and exclusive license agreement to develop a novel therapy for Alzheimer's ... via The South Mississippi Sun Herald

Worried that its partners might end a license deal early, depriving it of revenue, Neurobiological Technologies Inc. via Bizjournals

Neurobiological Technologies Inc. has received a royalty payment of approximately $2.1 million from Merz Pharmaceuticals GmbH and its marketing partners, the company said Wednesday. via East Bay Business Times

Neurobiological Technologies, Inc. ) today announced the date of its first annual Research & Development Day to be held on Tuesday, March 4, 2008. via Med Ad News

EMERYVILLE, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. via Earth Times

“Some products that were dogs could have a second or a third life.”

San Francisco Business Times - by Ron Leuty Najib Joe Hakim “We’ve been like Lazarus,” says Freiman of how his company resurrected Vipinex. via Bizjournals

“There was no disagreement or dispute between Dr. Cape and the company which led to his resignation”

Ronald Cape, who served on the board of Emeryville's Neurobiological Technologies Inc. via The San Francisco Business Times

“And we have, in the history of our company, licensed four products, and three have survived, one on the market, two in stage-three testing.”

NOVATO GOING TO STATE! Community Briefs Firefighters hold holiday toy program Out with the old, in with the new Novato Independent Business Alliance plans first meeting Homeward Bound of Marin offers charity ... via Novato Advance

“And we have, in the history of our company, licensed four products, and three have survived, one on the market, two in stage-three testing.”

The Olompali garden project Ali Mafi headlines Pacheco comedy night Marin Dance Theatre brings holiday season to life Events Calendar Musing on Novato: Car accident can change life course Our View: Let there be ... via Novato Advance